Loading clinical trials...
Loading clinical trials...
Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Conditions
Interventions
Venetoclax
Dinaciclib
Locations
13
United States
University of Arkansas /ID# 200016
Little Rock, Arkansas, United States
David Geffen School of Medicin /ID# 200015
Los Angeles, California, United States
The University ofChicago /ID# 200017
Chicago, Illinois, United States
University of Maryland School of Medicine /ID# 204015
Baltimore, Maryland, United States
Wake Forest Baptist Medical Center /ID# 200288
Winston-Salem, North Carolina, United States
The Ohio State University /ID# 200668
Columbus, Ohio, United States
Start Date
July 23, 2018
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2022
Last Updated
December 30, 2022
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions